T. Hoang

发表

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.

M. Socinski, S. Novello, F. Barlesi, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic Treatment of Small Cell Lung Cancer

J. Schiller, T. Hoang, 2002 .

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

Increased local failure risk with prolonged radiation treatment time in head and neck cancer treated with concurrent chemotherapy

P. Harari, T. McCulloch, H. Geye, 2014, Head & neck.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

J. Schiller, A. Sandler, J. Brahmer, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.

KyungMann Kim, J. Schiller, Paul E Koch, 2003, Lung cancer.

Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.

R. Jeraj, P. Harari, T. McCulloch, 2015, International journal of radiation oncology, biology, physics.

Induction of apoptosis in prostatic tumor cell line DU145 by staurosporine, a potent inhibitor of protein kinases

S. Ng, T. Hoang, Haichao Zhang, 1996, The Prostate.

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

J. Kolesar, KyungMann Kim, T. Campbell, 2014, Investigational New Drugs.

Phase I Study of Sunitinib and Erlotinib in Advanced Nonsquamous Non-small Cell Lung Cancer

KyungMann Kim, T. Campbell, S. Seo, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.

D. Cunningham, B. Karaszewska, M. Tejani, 2015 .

Augmentation of radiation response with the vascular targeting agent ZD6126.

P. Harari, J. Eickhoff, E. Armstrong, 2006, International journal of radiation oncology, biology, physics.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

G. Wilding, J. Kolesar, KyungMann Kim, 2013, Cancer Chemotherapy and Pharmacology.

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

D. Cunningham, B. Karaszewska, M. Tejani, 2017, The Lancet. Oncology.

Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer

T. Hensing, KyungMann Kim, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.

J. Siegfried, S. Dacic, J. Kolesar, 2009, Lung cancer.

Contributions of Targeted Agents

P. Harari, D. Wheeler, T. Hoang, 2009 .

Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data.

J. Schiller, R. Xu, P. Bonomi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.

J. Schiller, David H. Johnson, S. Dahlberg, 2013, Lung cancer.

Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.

M. Mehta, S. Belinsky, J. Schiller, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy

J. Schiller, T. Hoang, 2002, Expert review of anticancer therapy.

Enhancement of radiation response with bevacizumab

P. Harari, J. Eickhoff, E. Armstrong, 2012, Journal of experimental & clinical cancer research : CR.

Novel therapies for lung cancer.

J. Schiller, A. Traynor, T. Hoang, 2002, Surgical oncology.

Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma

P. Dhillon, H. Wakelee, R. Gutzmer, 2020, Oncoimmunology.

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

S. Novello, V. Papadimitrakopoulou, P. Dubray-Longeras, 2018, Journal of Thoracic Oncology.

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.

M. Socinski, F. Cappuzzo, V. Graupner, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Recent progress in therapeutic antibodies for cancer immunotherapy.

A. Sandler, Shawn W. Sun, Anthony Lee, 2018, Current opinion in chemical biology.

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

J. Grandis, P. Harari, A. Argiris, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer

Yilong Zhang, S. Doshi, M. Kuchimanchi, 2017, British journal of clinical pharmacology.

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study

KyungMann Kim, J. Schiller, G. Masters, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

M. Socinski, F. Cappuzzo, V. Graupner, 2018, Journal of Clinical Oncology.

Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).

N. Hanna, G. Clamon, H. West, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multistate Pharmacometric Model to Define the Impact of Second‐Line Immunotherapies on the Survival Outcome of the IMpower131 Study

M. Ballinger, F. Mercier, L. Friberg, 2023, Clinical pharmacology and therapeutics.

OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

M. Socinski, R. Soo, M. Mccleland, 2019, Journal of Thoracic Oncology.

375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC

M. Socinski, S. Novello, P. Dubray-Longeras, 2020 .

P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

Melissa L. Johnson, B. Cho, R. Meng, 2021 .

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.

M. Socinski, M. Nishio, A. Sandler, 2017 .

IMpower132: Efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC).

K. Goto, V. Papadimitrakopoulou, F. Barlesi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination therapy with gefitinib and fulvestrant (G/F) for women with non-small cell lung cancer (NSCLC)

J. Siegfried, J. Kolesar, J. Schiller, 2005 .

741TiPRILOMET-1: AN INTERNATIONAL PHASE 3 MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF RILOTUMUMAB PLUS EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED MET-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (G/GEJ) ADENOCARCINOMA.

D. Cunningham, N. Tebbutt, S. Al-Batran, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Gender associations in head and neck squamous cell carcinoma (HNSCC).

P. Harari, Menggang Yu, T. McCulloch, 2012 .

IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC.

M. Socinski, V. Graupner, R. Soo, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice

P. Dhillon, H. Wakelee, R. Gutzmer, 2019 .

Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study.

M. Mehta, S. Belinsky, J. Schiller, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

J. Kolesar, M. Jones, T. Campbell, 2011, Journal of Clinical Oncology.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

J. Schiller, David H. Johnson, A. Sandler, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.